Full-Time
Rotational Assignment Program
Posted on 2/7/2025
Medline
10,001+ employees
Manufacturer and distributor of medical supplies
Compensation Overview
$56.2k - $78.5k/yr
No H1B Sponsorship
Northbrook, IL, USA + 1 more
More locations: Chicago, IL, USA
 Business & Strategy (3) |
|---|
| , , |
People at Medline
People at Medline who can refer or advise you
- Bachelor’s Degree with a minimum 3.0 GPA
- Excellent organizational, planning, communication and follow-up skills required
- Excellent presentation skills for large and small groups
- Must have strategic, analytical and problem-solving skills
- Must have a bias toward action and be results oriented
- Proficient with Microsoft Office Suite including Excel, PowerPoint and Outlook
- Unrestricted permanent US work authorization
- Regularly perform duties core duties expected of Associate level professionals in the assigned division/team
- Contribute to team effort by accomplishing related results and common goals
- Research the market and performing analyses to determine new opportunities to grow the business
- Communicate with customers, reps, internal departments, and vendors, as needed
- Recommend and implement improvements, modifications or additions to current state
- Participate in overall strategy, competitive analyses, research and development requirements, as well as other duties as assigned
- Previous internship experience preferred
- Active interest in the Healthcare industry preferred
Medline Industries designs, produces, and distributes medical supplies for healthcare settings. It combines manufacturing and distribution to control product quality and sell directly to hospitals and other healthcare providers, offering a wide range of Medline-branded and third-party products. Its products include gowns, uniforms, gloves, and other medical consumables, produced and then delivered through a direct-to-provider model. The company differentiates itself with vertical integration that bypasses traditional distributors, a long-standing family-led culture that continued after a 2021 private-equity-led majority investment, and the scale to serve healthcare systems with a broad catalog. The goal is to supply healthcare providers with a comprehensive, high-quality catalog of medical products while expanding market reach and maintaining reliability through direct manufacturing-and-distribution control.
Company Size
10,001+
Company Stage
IPO
Headquarters
Northfield, Illinois
Founded
1966
People at Medline
People at Medline who can refer or advise you
Simplify's Take
What believers are saying
- Slovakia manufacturing expansion doubles capacity by 2027, strengthening European supply resilience and customer proximity
- Partnership with Access Vascular launches FDA-approved anti-thrombogenic catheters into $600M market by late 2026
- Northern California distribution footprint expanded 45% post-fire, securing 1.6M sq ft to maintain seamless supply chain operations
What critics are saying
- Persistent B. cereus contamination across multiple sites due to inadequate aseptic practices and failed corrective actions within 6-12 months
- FDA Class I recall of reprocessed catheters triggers immediate customer destruction orders and potential litigation in 3-6 months
- Second FDA warning letter in two months signals systemic management collapse and risk of market-wide shutdowns within 6-12 months
What makes Medline unique
- Medline uniquely combines manufacturing and distribution, controlling quality and selling directly to hospitals without traditional distributors
- Family-led culture persists despite 2021 private equity acquisition, preserving long-standing values while gaining resources for expansion
- Global footprint spans 100+ countries with 45,000 employees, offering unmatched scale in medical-surgical products and supply chain solutions
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Life Insurance
Disability Insurance
401(k) Company Match
Paid Vacation
Paid Sick Leave
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Highest FDA recall issued for certain catheters, heart pump controllers. Jun 23, 2026 - 03:50 PM The Food and Drug Administration has identified a Class I recall of reprocessed electrophysiology and ultrasound catheters by Medline Industries due to specific lots potentially containing small residual particles. The FDA said that all affected products should be destroyed after recall response actions are complete. The agency also identified a Class I recall of all Automated Impella Controllers by Abiomed due to the potential of an internal software error when a patient experiences a period longer than 80 minutes with no residual pulsatility. The Abiomed recall involves updating use instructions and does not involve removing them from where they are used or sold. The FDA also issued an early alert for catheter introducer kits by Abiomed and Oscor due to a potential for introducer sheath leakage.
Medline draws another US FDA warning in two months over quality lapses. By Thomson Reuters Jun 3, 2026 | 9:39 AM June 3 (Reuters) - The U.S. FDA issued a warning letter to medical device maker Medline over violations of manufacturing quality standards, the second such action against the company in two months. The Food and Drug Administration, in its letter dated May 28, said the company failed to thoroughly investigate microbial contamination incidents in finished drug products and also cited inadequate cleaning practices. This follows an FDA warning letter in April that flagged defects in Medline's syringes used in heart procedures and warned of enforcement action if the issues were not addressed. In its latest letter, the FDA said Medline's probe into the contaminated samples was inadequate and faulted the company for not explaining why earlier corrective actions had failed, warning that such lapses may pose a patient safety hazard. "Following an inspection of our ReadyCare Waukegan facility (in Illinois), we implemented significant improvements in our production processes and plant operations to ensure the highest levels of quality," the company said in an emailed response. The FDA has directed Medline to provide an independent risk assessment of all contamination hazards in its manufacturing processes, equipment and facilities, along with a remediation plan and timelines. The regulator said Medline's manufacturing operators have routinely deviated from cleaning and disinfection procedures, and also flagged manufacturing lapses at other facilities in the company's network. It added that "repeated failures at multiple sites" demonstrate inadequate management oversight and control, and said the company should assess its operations to ensure they conform to FDA requirements. The company said it is continuing to fully engage with the FDA related to both its Waukegan facility and its other drug manufacturing sites. Failure to address this matter may result in regulatory or legal action, the FDA said. The company must respond within 15 days of receiving the letter. (Reporting by Sneha S K in Bengaluru; Editing by Vijay Kishore)
Woman's Hospital selects Medline as its laboratory Prime Vendor. May 18, 2026 - Medline announced that it signed an expanded Prime Vendor agreement with Baton Rouge-based Woman's Hospital, which specializes in high-quality care for women and infants and is the largest delivery service in Louisiana and among the largest in the nation. The hospital provides maternity care, infant care, maternal mental health care and cancer treatment to patients across the state. With this new agreement, Woman's Hospital will have access to Medline's comprehensive portfolio of laboratory products, in addition to medical-surgical products. The agreement also provides access to Medline's distribution capabilities to help support more efficient ordering, improved inventory visibility and reliable delivery.
Medline neurosurgical sponge recall: A Staritas resource to support informed substitution decisions. On March 13, 2026, Medline announced a voluntary recall of its neurosurgical sponges due to elevated endotoxin levels. All affected products must be destroyed, and there is currently no timeline for return, creating an immediate supply disruption for providers that rely on these sponges for critical procedures. Neurosurgical sponges are essential in delicate operations where sterility, precision, and absorbency are non-negotiable. This recall presents more than a sourcing challenge. Clinical teams must rapidly evaluate alternatives, supply chain leaders must secure inventory in a constrained market, and finance teams must manage pricing volatility, all while ensuring continuity of care. To support providers navigating this disruption, Staritas has developed a Functional Equivalence Report identifying U.S. alternatives to the recalled Medline products. The report goes beyond a substitute list by offering structured comparisons across key clinical specifications such as size, materials, absorbency, and intended use. This approach helps teams assess safety and performance with confidence. The report also includes Supply Guide price benchmarks, giving supply chain and finance leaders critical visibility into market pricing at a time when demand shifts and cost pressures are high. Together, these insights empower faster, more informed decision-making, strengthen cross-functional alignment, and help make every choice clear. While recalls are disruptive, they also underscore the importance of preparedness, including clear cross-department communication, supplier diversification, and data-driven inventory management. With the right tools and insight, organizations can respond strategically rather than reactively. Staritas partners with healthcare organizations to navigate disruptions like this one by turning uncertainty into informed action and helping ensure patient care continues without compromise. Explore how Staritas Functional Equivalents and Recall Management solutions can help you quickly identify appropriate alternatives, assess risk exposure, and respond to disruptions with clarity and confidence.
Medline receives FDA warning letter on its heart procedure syringes. April 09, 2026 01:29 PM CDT The Food and Drug Administration has sent a warning letter to Medline Industries over reported issues with syringes used in cardiac procedures and the company could face regulatory action if the issues are not corrected. Staying current is easy with newsletters delivered straight to your inbox.